Lavoz Carolina, Rayego-Mateos Sandra, Orejudo Macarena, Opazo-Ríos Lucas, Marchant Vanessa, Marquez-Exposito Laura, Tejera-Muñoz Antonio, Navarro-González Juan F, Droguett Alejandra, Ortiz Alberto, Egido Jesús, Mezzano Sergio, Rodrigues-Diez Raúl R, Ruiz-Ortega Marta
Laboratorio de Nefrología, Facultad de Medicina, Universidad Austral de Chile, 5090000 Valdivia, Chile.
Vascular and Renal Translational Research Group, Institut de Recerca Biomèdica de Lleida (IRBLleida), 25198 Lleida, Spain.
J Clin Med. 2020 Jan 19;9(1):272. doi: 10.3390/jcm9010272.
Chronic kidney disease has become a major medical issue in recent years due to its high prevalence worldwide, its association with premature mortality, and its social and economic implications. A number of patients gradually progress to end-stage renal disease (ESRD), requiring then dialysis and kidney transplantation. Currently, approximately 40% of patients with diabetes develop kidney disease, making it the most prevalent cause of ESRD. Thus, more effective therapies for diabetic nephropathy are needed. In preclinical studies of diabetes, anti-inflammatory therapeutic strategies have been used to protect the kidneys. Recent evidence supports that immune cells play an active role in the pathogenesis of diabetic nephropathy. Th17 immune cells and their effector cytokine IL-17A have recently emerged as promising targets in several clinical conditions, including renal diseases. Here, we review current knowledge regarding the involvement of Th17/IL-17A in the genesis of diabetic renal injury, as well as the rationale behind targeting IL-17A as an additional therapy in patients with diabetic nephropathy.
近年来，慢性肾脏病已成为一个重大的医学问题，这是由于其在全球范围内的高患病率、与过早死亡的关联以及其社会和经济影响。许多患者会逐渐发展为终末期肾病（ESRD），进而需要透析和肾脏移植。目前，约40%的糖尿病患者会发展为肾病，这使其成为ESRD最常见的病因。因此，需要更有效的糖尿病肾病治疗方法。在糖尿病的临床前研究中，抗炎治疗策略已被用于保护肾脏。最近的证据支持免疫细胞在糖尿病肾病的发病机制中发挥积极作用。Th17免疫细胞及其效应细胞因子IL-17A最近在包括肾脏疾病在内的几种临床病症中已成为有前景的治疗靶点。在此，我们综述了关于Th17/IL-17A参与糖尿病性肾损伤发生的现有知识，以及将IL-17A作为糖尿病肾病患者额外治疗靶点的基本原理。
